These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6420928)

  • 1. The interaction between collagens and factor VIII/von Willebrand factor: investigation of the structural requirements for interaction.
    Morton LF; Griffin B; Pepper DS; Barnes MJ
    Thromb Res; 1983 Dec; 32(6):545-56. PubMed ID: 6420928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III.
    Houdijk WP; Sakariassen KS; Nievelstein PF; Sixma JJ
    J Clin Invest; 1985 Feb; 75(2):531-40. PubMed ID: 3919060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional domains on von Willebrand factor. Recognition of discrete tryptic fragments by monoclonal antibodies that inhibit interaction of von Willebrand factor with platelets and with collagen.
    Sixma JJ; Sakariassen KS; Stel HV; Houdijk WP; In der Maur DW; Hamer RJ; de Groot PG; van Mourik JA
    J Clin Invest; 1984 Sep; 74(3):736-44. PubMed ID: 6332119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Collagen-factor VIII/von Willebrand factor protein interaction.
    Kessler CM; Floyd CM; Rick ME; Krizek DM; Lee SL; Gralnick HR
    Blood; 1984 Jun; 63(6):1291-8. PubMed ID: 6426548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.
    Fischer BE; Kramer G; Mitterer A; Grillberger L; Reiter M; Mundt W; Dorner F; Eibl J
    Thromb Res; 1996 Oct; 84(1):55-66. PubMed ID: 8885147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation.
    Kao KJ; Pizzo SV; McKee PA
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5317-20. PubMed ID: 315561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets.
    Kao KJ; Pizzo SV; McKee PA
    J Clin Invest; 1979 Apr; 63(4):656-64. PubMed ID: 108291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding.
    Li X; Gabriel DA
    Biochemistry; 1997 Sep; 36(35):10760-7. PubMed ID: 9271507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.
    Ruggeri ZM; Pareti FI; Mannucci PM; Ciavarella N; Zimmerman TS
    N Engl J Med; 1980 May; 302(19):1047-51. PubMed ID: 6767976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain.
    Hamer RJ; Koedam JA; Beeser-Visser NH; Bertina RM; Van Mourik JA; Sixma JJ
    Eur J Biochem; 1987 Jul; 166(1):37-43. PubMed ID: 3109914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.
    Ramasamy I; Farrugia A; Tran E; Anastasius V; Charnock A
    Biologicals; 1998 Jun; 26(2):155-66. PubMed ID: 9811523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.
    Ågren A; Holmström M; Schmidt DE; Hosokawa K; Blombäck M; Hjemdahl P
    Thromb Haemost; 2017 Jan; 117(1):75-85. PubMed ID: 27761577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
    Karlman M; Holmström M; Wiman B
    Thromb Res; 2011 Jan; 127(1):47-50. PubMed ID: 21094987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.
    Neugebauer BM; Goy C; Budek I; Seitz R
    Semin Thromb Hemost; 2002 Apr; 28(2):139-48. PubMed ID: 11992237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A qualitative and quantitative analysis of von Willebrand factor contained in a very high-purity plasma-derived FVIII concentrate.
    Samor B; Michalski C; Brandin MP; Andre MH; Chtourou S; Tellier Z
    Vox Sang; 2012 Jul; 103(1):35-41. PubMed ID: 22239246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
    Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.